TOKYO, Dec. 16 /PRNewswire/ -- Today Sosei Co. Ltd., a leading Japanese biopharmaceutical company, and Nippon Organon K.K. announced that the companies have agreed to enter into a collaboration for the co-promotion of SOT-375, a product being developed by Sosei for the indication of prostate cancer. Sosei in-licensed Eligard(R), currently marketed in the United States by Sanofi-Synthelabo, from Atrix Laboratories, Inc. in January 2003 and holds exclusive rights to develop and commercialise in Japan. Sosei has already started clinical trials of the product as SOT-375 in Japan to obtain marketing approval.
SOT-375 is a new patient-friendly leuprolide acetate (LHRH agonist) formulation developed by Atrix using Atrix's Atrigel(R) delivery system. The product is a highly effective palliative treatment indicated for hormone-responsive prostate cancer. The Japanese market for LHRH agonist therapies is $600 million which is estimated to grow with the rapidly aging society. Eligard(R) one-month, three-month and four-month products have been approved by the FDA for the treatment of prostate cancer and are marketed in the United States by Sanofi-Synthelabo. These have also been licensed in the European, Oceanic and Canadian markets.
Willem J. Kleijn, President of Nippon Organon said: "We are very pleased to announce this collaboration, an opportunity to reinforce our position in the field of urology, one of our key therapeutic areas. The synergy effects expected from marketing together with Avishot will surely strengthen our position."
Shin-Ichi Tamura, President & CEO of Sosei commented: "It is my pleasure to collaborate for the co-promotion of our first product with Nippon Organon who have a big advantage in the marketing of urology products. This category represents one of Japan's largest therapeutic drug classes in oncology and I have great expectations of this partnership."
About Sosei Co. Ltd.
Sosei Co. Ltd. (Tokyo, Japan and London, UK), founded in 1990, by Mr. Shinichi Tamura the ex-CEO of Genentech Japan, is a leading Japanese biopharmaceutical company with significant expertise in drug development. It enriches the core product pipeline via in-licensing compounds from Western and Japanese companies, by its distinctive Drug Reprofiling Platform(TM) (DRP(R)) and through R&D programmes in collaboration with biopharmaceutical companies and universities both in Japan and the West. Sosei is also developing its own sales and marketing organisation. The company is capitalising on its extensive global network established over the past 10 years in its successful technology transfer business. Sosei's investors include experienced US/EU funds and Japanese institutional investors. For further information about Sosei, please visit http://www.sosei.com/.
About Nippon Organon K.K.
Nippon Organon K.K., founded in 1960 and reinforced by acquiring a part of pharmaceutical division of Kanebo, Ltd. in 1999, is a subsidiary of Organon International Inc. Organon -headquartered in Roseland, NJ, USA- creates and markets prescription medicines that improve the health and quality of human life. Organon's core therapeutic fields are gynecology, central nervous system, cardiovascular disease and anesthesiology. Organon is the human health care business unit of Akzo Nobel. For further information about Nippon Organon, please visit http://www.organon.co.jp/.
Sosei Co. Ltd.; Nippon Organon K.K.
CONTACT: Tokyo: Toshio Miyashita, Director of Corporate Planning,+3-5210-3399, Fax: 3-5210-3291, firstname.lastname@example.org, London: John Daffurn,General Manager, +20-7691-2086, Fax: 20-7419-5984, email@example.com, both ofSosei Co. Ltd.; or Yukako Takabe, General Affairs Department of Nippon OrganonK.K., +6-6347-9766, Fax: 6-6347-9950, Yukako.Takabe@organon.jp